Rejected from The BMJ? The 7 Best Journals to Submit Next

Originality. The BMJ won't publish confirmatory studies unless they address a genuine clinical controversy. If your findings align with existing evidence, the editors will ask what's new. A large trial confirming that exercise reduces cardiovascular risk isn't going to make it, no matter how well-designed.

Relevance to a general medical audience. This is the most common rejection trigger. The BMJ's readers span all medical specialties, and the editors need to believe that a gastroenterologist, a psychiatrist, and a GP will all find the paper worth reading. Highly specialized clinical research, even if excellent, gets routed to specialty journals.

Sound study design. The BMJ checks reporting compliance early. Missing CONSORT diagrams for trials, STROBE checklists for observational studies, or PRISMA compliance for reviews can trigger desk rejection. The journal has publicly stated that editors can reject papers within the first hour if compliance gaps are obvious.

"Important findings but more suited to a specialist audience." You submitted a well-designed dermatology trial to The BMJ. It's excellent work, but dermatology-specific findings don't typically interest the journal's general readership. This rejection means your paper is competitive but in the wrong venue.

"The study design has limitations that reduce our confidence in the findings." The BMJ's statistical reviewers are thorough. Observational studies with unmeasured confounding, trials with high dropout rates, or analyses with multiplicity issues get flagged quickly.

"We have recently published on this topic." Bad timing. The BMJ tries to space out publications on similar themes. Your paper could be strong but simply arrived when the topic was saturated.

"The findings are primarily of regional interest." The BMJ has a global readership. Studies focused exclusively on one country's healthcare system, without discussing implications for other settings, can be rejected for limited generalizability.

The BMJ publishes a range of specialty journals, and editors sometimes suggest transfers:

• BMJ Open (IF ~3) - Broad scope, higher acceptance rate (~50%)
• BMJ Quality and Safety (IF ~6) - Patient safety and quality improvement
• BMJ Global Health (IF ~8) - Global health research
• Heart (IF ~6) - Cardiology
• Gut (IF ~25-26) - Gastroenterology and hepatology
• Thorax (IF ~10) - Respiratory medicine
• Annals of the Rheumatic Diseases (IF ~20) - Rheumatology

BMJ Open is the most common transfer destination. Don't dismiss it because of the lower IF. BMJ Open accepts roughly 50% of submissions, provides open access, and is indexed in PubMed. For papers that are sound but not quite competitive for The BMJ, it's a legitimate home.

Before choosing your next journal, a The BMJ manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. The Lancet

If The BMJ rejected your paper but the clinical evidence is strong and has global implications, The Lancet is the most ambitious alternative. The Lancet's editorial filter is similar to The BMJ's in prioritizing global relevance, but The Lancet accepts slightly fewer papers and expects larger-scale evidence.

The BMJ and The Lancet share a UK editorial heritage and similar values around evidence-based medicine and global health equity. A paper that was rejected from The BMJ for being "not quite impactful enough" for their readership might be rejected from The Lancet for the same reason. But if The BMJ's rejection was about space or timing rather than impact, The Lancet is worth trying.

Best for: Large clinical trials with global health implications, public health research with practice-changing potential.

2. JAMA

JAMA is the strongest alternative for clinical research that The BMJ found "too US-focused" or "of primarily regional interest." JAMA's readership is heavily North American, and the journal values studies relevant to US clinical practice. What The BMJ considers too regional for its global audience is exactly what JAMA wants.

JAMA also publishes more surgical, procedural, and specialty-spanning clinical research than The BMJ. If your paper sits at the intersection of multiple specialties and The BMJ thought it was too specialized, JAMA's slightly different editorial lens might see it differently.

Best for: US-focused clinical research, surgical trials, health services research with North American implications.

3. BMJ Open

BMJ Open is The BMJ's broad-scope open-access journal. It publishes clinical research, systematic reviews, study protocols, and observational studies with a much higher acceptance rate (~50%). The key criteria are sound methodology and transparent reporting, not novelty or perceived impact.

For papers The BMJ rejected on impact grounds rather than quality grounds, BMJ Open is the most efficient path. Your paper stays within the BMJ ecosystem, the editorial processes are familiar, and the acceptance timeline is faster.

The APC ($2,365) is lower than most competitors' open-access fees. Check whether your institution has a BMJ Read and Publish agreement.

Best for: Methodologically sound studies rejected from The BMJ for insufficient novelty or impact. Study protocols, pilot studies, and observational research.

4. PLOS Medicine

PLOS Medicine is the top open-access general medical journal, and it shares many of The BMJ's editorial values: global health, evidence-based policy, methodological rigor, and transparent reporting. If your paper has a global health dimension and you want open-access reach, PLOS Medicine is The BMJ's closest open-access equivalent.

PLOS Medicine also publishes policy forums, research essays, and other formats that clinical journals typically don't. If your paper includes a strong policy component, PLOS Medicine has more room for that content.

Best for: Global health research, evidence synthesis with policy implications, health equity studies.

5. Annals of Internal Medicine

Annals is the American College of Physicians' journal, and it publishes research that informs internal medicine practice and clinical guidelines. If The BMJ rejected your paper for being "too specialized" within internal medicine, Annals might see that specialization as a strength.

Annals publishes the ACP clinical guidelines and clinical practice reviews, so papers with guideline-informing potential carry extra weight here. Systematic reviews and evidence assessments are particularly well-suited.

Best for: Internal medicine research, systematic reviews that inform guidelines, screening and prevention studies.

6. CMAJ

CMAJ (Canadian Medical Association Journal) is a strong general medical journal with an IF around 9. It publishes clinical research, reviews, and commentary with both Canadian and international scope. For papers that The BMJ found "primarily of regional interest" but that have relevance to Commonwealth healthcare systems, CMAJ is worth considering.

CMAJ reviews tend to be constructive, and the journal's acceptance rate (~10%) is more accessible than The BMJ's. The journal publishes in both English and French, which can increase readership in francophone regions.

Best for: General medical research with relevance to Canadian or Commonwealth healthcare, public health research, health services studies.

7. International Journal of Epidemiology

For epidemiological studies that The BMJ rejected, IJE is the top specialty journal in the field. The BMJ publishes epidemiology within its general medical pages, but IJE provides a home specifically for methodological and applied epidemiology.

IJE is published by Oxford University Press and has a strong tradition of publishing cohort profiles, methodological papers, and large-scale epidemiological analyses. If your study's primary contribution is epidemiological rather than clinical, IJE is where it will reach the right audience.

Best for: Epidemiological studies, cohort analyses, methods papers, and population health research.

Clinical trial rejected at the desk? Try The Lancet (if globally relevant) or JAMA (if US-focused). If both are too selective, consider BMJ Open for rapid open-access publication.

Systematic review rejected? Annals of Internal Medicine is the strongest alternative. PLOS Medicine also publishes evidence synthesis. If the review is methodological, the Cochrane Database of Systematic Reviews is the gold standard.

Observational study rejected? BMJ Open accepts sound observational research at a high rate. International Journal of Epidemiology is strong for epidemiological analyses. PLOS Medicine values observational studies with global health implications.

Rejected after peer review? The BMJ uses open peer review, so you have named reviewers and detailed feedback. Address every point before resubmitting. The Lancet, JAMA, and Annals may request your existing reviews, which can speed up their process.

Check your reporting compliance. The BMJ auto-checks CONSORT, STROBE, and PRISMA adherence. If compliance gaps triggered your rejection, fix them before submitting anywhere. Every top medical journal checks the same standards.

Broaden or narrow your framing. If The BMJ said "too specialized," keep the specialty focus and submit to a specialty journal. If The BMJ said "too regional," consider adding a discussion section paragraph on generalizability to other healthcare systems.

Strengthen the "so what." The BMJ wants every paper to change clinical practice or policy. If your findings are statistically significant but clinically marginal, your cover letter needs to make the case for why the findings matter to practicing doctors.

Run your manuscript through a manuscript scope and readiness check to check formatting, reporting compliance, and scope alignment before your next submission.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• You can address concerns within 2-3 months

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Your timeline needs a decision within 2-3 months

Reframe before resubmitting if:

• Reviewers found fundamental methodology concerns
• New experiments are needed to support the claims

In our pre-submission review work with manuscripts targeting The BMJ, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Specialty findings without relevance to the general medical audience. The BMJ's readers span all medical specialties, and editors require that the paper's central finding interests a gastroenterologist, a psychiatrist, and a general practitioner simultaneously. We see this failure as the most common pattern in BMJ desk rejections we review: clinically strong papers whose significance is clearly visible to specialists in the relevant subspecialty but not self-evident to generalists. In our review of BMJ submissions, we find that editors consistently redirect papers where the cross-specialty relevance requires domain expertise to appreciate.

Confirmatory studies without a genuine clinical controversy to resolve. The BMJ does not publish large studies confirming what the field already knows, regardless of how well-designed the study is. We see this pattern in BMJ submissions we review address a question that the clinical community has already answered from prior evidence, with the new study adding statistical mass to an established consensus rather than resolving genuine uncertainty.

Reporting compliance gaps visible at the desk. The BMJ checks CONSORT, STROBE, and PRISMA compliance early in the editorial process. We see this regularly in manuscripts we review for The BMJ: missing flow diagrams in randomized trial submissions, absent STROBE checklists for observational studies, or PRISMA gaps in systematic reviews. These compliance failures generate returns before the paper reaches statistical review.

Observational studies with unaddressed confounding that limits causal inference. The BMJ's statistical reviewers are thorough and specifically screen for unmeasured confounding, reverse causation, and selection bias in observational designs. Papers drawing strong causal conclusions from cohort or registry data without addressing these limitations face consistent editorial concern.

SciRev community data for The BMJ confirms desk decisions typically within 1-2 weeks and post-review first decisions within 4-6 weeks.